Finch Therapeutics Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FNCH research report →
Range $159.98 – $159.98
Price Chart
About the company
Finch Therapeutics is a microbiome technology company with a portfolio of intellectual property and microbiome assets. The company is now focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations after winding down development efforts.
- CEO
- Matthew Blischak
- IPO
- 2021
- Employees
- 1
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on FNCH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.38M
- P/E
- -1.20
- Fwd P/E
- 0.19
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 1.83
- EV/EBITDA
- -2.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -86.83%
- ROIC
- -38.62%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-174,000+87.7%
- Op Income
- $-18,859,000
- Net Income
- $-13,877,000+81.4%
- EPS
- $-8.64+81.5%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $16.10
- 52W Low
- $2.00
- 50D MA
- $12.77
- 200D MA
- $12.96
- Beta
- 1.48
- RSI (14)
- 15
- Avg Volume
- 3.65K
No earnings-call transcripts are available for FNCH yet.
- Free Float
- 55.8%
- Shares Outstanding
- 1.61M
- Float Shares
- 896.19K
of shares held by institutions
10 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Avenir Management Company, LLC | 45.65K | ▼ 9.79K |
Our FNCH coverage
Recent articles, reports, and earnings notes.
No research on FNCH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FNCH report →Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.7% – Here’s What Happened
defenseworld.net · Mar 19
Critical Contrast: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Finch Therapeutics Group (NASDAQ:FNCH)
defenseworld.net · Jan 22
Contrasting Finch Therapeutics Group (NASDAQ:FNCH) and Eloxx Pharmaceuticals (NASDAQ:ELOX)
defenseworld.net · Jan 22
Financial Survey: ZIVO Bioscience (NASDAQ:ZIVO) versus Finch Therapeutics Group (NASDAQ:FNCH)
defenseworld.net · Jan 6
Arquitos Capital's Largest Holdings For Q1 2025
seekingalpha.com · Apr 30
Finch Announces Delisting from Nasdaq and SEC Deregistration
globenewswire.com · Oct 21
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%
pennystocks.com · Apr 19
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.